Drug WatchNew Drug Targets Key Genetic Driver of CancerAschenbrenner, Diane S. MS, RNAuthor Information Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: email@example.com. AJN, American Journal of Nursing: December 2019 - Volume 119 - Issue 12 - p 21 doi: 10.1097/01.NAJ.0000615768.79290.14 Buy Metrics Abstract Entrectinib (Rozlytrek) has been approved by the Food and Drug Administration to treat adolescent and adult patients whose solid tumor cancers are related to a specific genetic defect known as neurotrophic tyrosine receptor kinase gene fusion, and for whom there are no effective treatments. Several warnings and precautions are listed on entrectinib's labeling, including congestive heart failure, central nervous system effects, skeletal fractures, hepatotoxicity, hyperuricemia, QT interval prolongation, vision disorders, and embryo–fetal toxicity. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.